QED@QB3 Seminars

Lila Hope, Cooley LLP

“The first deal—small contract terms with big consequences”
Wednesday, May 16, 4—5 pm (happy hour to follow)
UCSF Mission Bay, Byers Hall, Room 212
Sold out

Dr. Hope will lay out some of the key elements in early stage licenses and research collaborations that a startup company may enter into, as well as how such terms may play out as the company seeks collaboration partners as its product and technology mature over time.

Dr. Lila W. Hope is a partner in the Life Sciences practice group and counsels life sciences clients ranging from privately-held companies to Fortune 500 companies. She specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and complex asset purchases. In addition, she counsels clients’ management, operational and legal teams on daily legal matters involving grant funding, licensing, supply, distribution, clinical trials, research collaborations and contract services. She is regularly involved in financing and M&A transactions where she evaluates a company’s product rights and operational risks through contract due diligence. Dr. Hope graduated with a J.D. magna cum laude from Duke University School of Law. She earned her Ph.D. in Cancer Biology from Stanford University School of Medicine. Prior to entering Stanford, she graduated with an M.S. from the Oregon Graduate Institute, and received her undergraduate education at the University of San Francisco and the University of Science and Technology of China.

Joseph Snyder, Kilpatrick Townsend

“Prometheus v Mayo”
Thursday, June 7, noon—1 pm
UCSF Mission Bay, Byers Hall, Room 212
Register

Mayo Medical Laboratories v Prometheus Laboratories Inc.

Dr. Snyder will discuss the recent decision in the Supreme Court case and its implication on patentable subject matter in biotechnology. Dr. Snyder will also review earlier Supreme Court precedent in order to further explain the Court’s view on patentable subject matter and the patent laws prohibition on patenting laws of nature, natural phenomena and abstract ideas.

Joseph Snyder is the Managing Partner of the firm’s Walnut Creek office. He focuses his practice on patent prosecution and counseling, emphasizing patent drafting, patent procurement, client counseling and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies’ commercial potential, enforcement of patent rights and defense of infringement allegations. Dr. Snyder represents U.S. and foreign companies, such as pharmaceutical companies, diagnostic laboratories, universities and start-ups in all areas of intellectual property counseling and protection.

He conducts and performs due diligence investigations in connection with commercial transactions, such as mergers, acquisitions and the establishment of strategic business alliances. These investigations involve intellectual property including patents, technology licenses, acquisition agreements and asset purchase agreements. Dr. Snyder advises on the creation of start-ups and their patent portfolio development. He coordinates and negotiates the transfer and licensing of intellectual property as it relates to office of technology transfer agreements, collaborative/sponsored research agreements and other transfer agreements.

His technology experience includes small molecules, pharmaceutical formulations, drug delivery technologies, medical diagnostics, nucleic acid assays, nucleic acid sequencing technologies, dyes and clean technology, such as fuel cells.

Before joining the firm, Dr. Snyder worked as a patent attorney for Zeneca Ag Products in the areas of patent drafting, patent prosecution and patent validity opinions.

Prior to joining the legal profession, he was a senior scientist in their analytical department doing organic structural analysis using NMR and mass spectrometry.

David Kirn, Founder, President & CMO, Jennerex Biotherapeutics, Inc.

“Targeted and transgene-armed oncolytic poxviruses for cancer: clinical proof-of-concept and future directions”
Wednesday, June 13, 4—5 pm (happy hour to follow)
UCSF Mission Bay, Byers Hall, Room 212
Register

Dr. Kirn is the global leader in the clinical research and development of oncolytic viruses for cancer. He designed and led clinical development programs and trials with over 10 different agents, and with over 10 different companies and leading academic programs, involving hundreds of patients (Phase 1-3). He held academic and/or faculty positions at Harvard Medical School; the University of California, San Francisco (UCSF); and the University of Oxford. In addition, Dr. Kirn was vice president of clinical research at Onyx Pharmaceuticals. After joining Onyx as the first oncology development employee, he created and initiated clinical development plans in partnership with Bayer for Nexavar, now a marketed product for kidney and liver cancers. He also led the development of a first-in-class oncolytic virus therapeutic through to Phase 3, a corporate partnership with Warner-Lambert and an initial public offering during his tenure. He has been a consultant in cancer biotherapeutics for Pfizer, Novartis, BiogenIdec, Schering AG and other leading oncology companies. He has been an invited advisor on cancer therapy to the National Institutes of Health (U.S.), the Gene Therapy Advisory Committee (U.K.) and the European Agency for the Evaluation of Medicinal Products (E.U.). He has authored over 100 publications in peer-reviewed journals and textbooks. He completed his oncology fellowship at UCSF, his internal medicine residency at Brigham and Women’s Hospital, a teaching affiliate of Harvard and was chief medical resident (WR-VA) at Harvard Medical School. He received his MD from UCSF (AOA Honors) and his BS in physiology from the University of California, Berkeley, with departmental citation, Phi Beta Kappa.